Evidence map›Paper›PMID 36128671›Full record

ReviewEpidemiology and infection2022

Renal, cardiac, neurological, cutaneous and coagulopathic long-term manifestations of COVID-19 after recovery; A review.

Reza Afrisham, Yasaman Jadidi, Maryam Davoudi, Kiana Moayedi, Saina Karami, Sahar Sadegh-Nejadi, Damoon Ashtary-Larky, ShadiSadat Seyyedebrahimi, Shaban Alizadeh

Abstract readReview
In one paragraph

Review in Epidemiology and infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Reza AfrishamDepartment of Clinical Laboratory Sciences, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Yasaman JadidiDepartment of Clinical Laboratory Sciences, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Maryam DavoudiDepartment of Clinical Laboratory Sciences, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Kiana MoayediDepartment of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Saina KaramiStudent research committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Sahar Sadegh-NejadiDepartment of Clinical laboratory, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Damoon Ashtary-LarkyNutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
ShadiSadat SeyyedebrahimiDepartment of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Shaban AlizadehDepartment of Hematology and Transfusion Medicine, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-1716-7072

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the novel global coronavirus disease 2019 (COVID-19) disease outbreak. Its pathogenesis is mostly located in the respiratory tract. However, other organs are also affected. Hence, realising how such a complex disturbance affects patients after recovery is crucial. Regarding the significance of control of COVID-19-related complications after recovery, the current study was designed to review the cellular and molecular mechanisms linking COVID-19 to significant long-term signs including renal and cardiac complications, cutaneous and neurological manifestations, as well as blood coagulation disorders. This virus can directly influence on the cells through Angiotensin converting enzyme 2 (ACE-2) to induce cytokine storm. Acute release of Interleukin-1 (IL1), IL6 and plasminogen activator inhibitor 1 (PAI-1) have been related to elevating risk of heart failure. Also, inflammatory cytokines like IL-8 and Tumour necrosis factor-

Indexed as

Blood Coagulation DisordersCOVID-19Heart DiseasesKidney DiseasesNervous System DiseasesPost-Acute COVID-19 SyndromeSkin DiseasesSARS-CoV-2Blood coagulation disorderscardiac diseaseCOVID-19kidneyneurological disorderskin diseases

Identifiers

PMID36128671
PMCPMC10212601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.